Lp(a) medicines trials

5 studies from 2020 to 2025, with 1,298 people taking part. Results: 5 lipid or plaque goal met. Every summary comes from the trial's PubMed abstract.

Fewer heart events or deaths
No clear benefit
Lipid or plaque goal met
Safety, side effects or genetics

1984 to 20265 studies, 1,298 people in trials

Circle size shows how many people took part. Tap a circle to open the trial; on a phone, swipe sideways for earlier years. The people count leaves out meta-analyses and genetic studies, which pool other studies.

All 5 studies

ALPACA2025 · Lepodisiran · 320 people
Lepodisiran produced large, dose-dependent and durable reductions in serum lipoprotein(a) with generally mild injection-site reactions, but this trial did not assess cardiovascular outcomes.
Primary lipid endpoint metLp(a) medicinesInvestigational
KRAKEN2025 · Muvalaplin · 233 people
Oral muvalaplin produced large, dose-dependent reductions in lipoprotein(a) over 12 weeks with no safety or tolerability concerns, though whether this translates into fewer cardiovascular events is still unknown.
Primary lipid endpoint metLp(a) medicinesInvestigational
ALPACA (zerlasiran phase 2)2024 · Zerlasiran · 178 people
In patients with established atherosclerotic cardiovascular disease and very high Lp(a), zerlasiran safely lowered Lp(a) levels by more than 80% on average over 36 weeks compared with placebo.
Primary lipid endpoint metLp(a) medicinesInvestigational
OCEAN(a)-DOSE2022 · Olpasiran · 281 people
Olpasiran markedly and dose-dependently lowered lipoprotein(a) levels in patients with established atherosclerotic cardiovascular disease and elevated Lp(a), with similar overall adverse event rates to placebo, but whether this translates into reduced cardiovascular events remains to be determined.
Primary lipid endpoint metLp(a) medicinesInvestigational
Pelacarsen phase 22020 · Pelacarsen · 286 people
In patients with cardiovascular disease and elevated Lp(a), the antisense drug APO(a)-LRx (pelacarsen) lowered Lp(a) levels in a dose-dependent manner, with no significant safety signals versus placebo, though cardiovascular outcomes were not assessed in this trial.
Primary lipid endpoint metLp(a) medicinesInvestigational

Other medicines

Search and filter all 106 studies in the trial database. Education only, not medical advice.

Get your LDL treated to a goal.

We're rolling out services slowly and taking a limited number of patients. Join the waitlist to get an early spot.

Join the Waitlist